Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes
出版年份 2018 全文链接
标题
Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes
作者
关键词
-
出版物
ANNALS OF HEMATOLOGY
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-11-10
DOI
10.1007/s00277-018-3539-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Iron overload in Myelodysplastic Syndromes: Evidence Based Guidelines from the Canadian Consortium on MDS
- (2018) Heather A. Leitch et al. LEUKEMIA RESEARCH
- Thalassemia Minor and Major: Current Management
- (2017) Ved Prakash Choudhry INDIAN JOURNAL OF PEDIATRICS
- Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years
- (2017) Roger M. Lyons et al. LEUKEMIA RESEARCH
- Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies
- (2017) Ivo Abraham et al. LEUKEMIA RESEARCH
- Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
- (2017) Maximilian Stahl et al. Expert Review of Hematology
- MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
- (2017) Emanuele Angelucci et al. Mediterranean Journal of Hematology and Infectious Diseases
- The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions
- (2016) Eun-Ju Lee et al. BLOOD REVIEWS
- Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
- (2016) Nicole Carreau et al. BLOOD REVIEWS
- Comparative clinical effectiveness of azacitidineversusdecitabine in older patients with myelodysplastic syndromes
- (2016) Amer M. Zeidan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Emerging biological therapies for the treatment of myelodysplastic syndromes
- (2016) Amer M. Zeidan et al. EXPERT OPINION ON EMERGING DRUGS
- Molecular pathogenesis and clinical consequences of iron overload in liver cirrhosis
- (2016) Katarzyna Sikorska et al. Hepatobiliary & Pancreatic Diseases International
- New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities
- (2016) Abdallah Abou Zahr et al. Expert Review of Hematology
- Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry
- (2016) Anna Waszczuk-Gajda et al. Advances in Clinical and Experimental Medicine
- Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
- (2015) Amer M. Zeidan et al. AMERICAN JOURNAL OF HEMATOLOGY
- Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
- (2015) Guillermo Garcia-Manero AMERICAN JOURNAL OF HEMATOLOGY
- Current state of prognostication and risk stratification in myelodysplastic syndromes
- (2015) Amer M. Zeidan et al. CURRENT OPINION IN HEMATOLOGY
- The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes
- (2015) Abdallah Abou Zahr et al. Expert Review of Anticancer Therapy
- Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome – Emphasis on optimized dosing schedules and new formulations
- (2015) Florian Nolte et al. LEUKEMIA RESEARCH
- Iron-Induced Damage in Cardiomyopathy: Oxidative-Dependent and Independent Mechanisms
- (2015) Elena Gammella et al. Oxidative Medicine and Cellular Longevity
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
- (2015) Amer M Zeidan et al. Journal of Comparative Effectiveness Research
- Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
- (2014) Ángel F. Remacha et al. ANNALS OF HEMATOLOGY
- The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome
- (2014) Arch G. Mainous et al. BRITISH JOURNAL OF HAEMATOLOGY
- Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
- (2014) Michel Delforge et al. LEUKEMIA RESEARCH
- Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia
- (2013) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS)
- (2013) Amer M. Zeidan et al. AMERICAN JOURNAL OF MEDICINE
- Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
- (2013) Amer M. Zeidan et al. CURRENT OPINION IN HEMATOLOGY
- Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry
- (2013) Roger M. Lyons et al. LEUKEMIA RESEARCH
- Iron overload in children undergoing cancer treatments
- (2013) Maëlle de Ville de Goyet et al. PEDIATRIC BLOOD & CANCER
- Iron chelation therapy in myelodysplastic syndromes: where do we stand?
- (2013) Mhairi Mitchell et al. Expert Review of Hematology
- There’s Risk, and Then There’s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes
- (2013) Amer M. Zeidan et al. Current Hematologic Malignancy Reports
- Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome
- (2012) Alan F. List et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved survival in MDS patients receiving iron chelation therapy – A matched pair analysis of 188 patients from the Düsseldorf MDS registry
- (2012) Judith Neukirchen et al. LEUKEMIA RESEARCH
- Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis
- (2012) Heather A. Leitch et al. LEUKEMIA RESEARCH
- Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Controversies surrounding iron chelation therapy for MDS
- (2010) Heather A. Leitch BLOOD REVIEWS
- Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
- (2010) Christian Rose et al. LEUKEMIA RESEARCH
- Myelodysplastic Syndromes
- (2009) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices
- (2009) Anastasios Raptis et al. TRANSFUSION
- Consensus statement on iron overload in myelodysplastic syndromes
- (2008) John M. Bennett et al. AMERICAN JOURNAL OF HEMATOLOGY
- Myelodysplastic syndromes
- (2008) S. D. Nimer BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started